BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34239264)

  • 1. Natural killer cells in pancreatic cancer stroma.
    Fincham REA; Delvecchio FR; Goulart MR; Yeong JPS; Kocher HM
    World J Gastroenterol; 2021 Jun; 27(24):3483-3501. PubMed ID: 34239264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles.
    Kumar V; Mahato RI
    Cancer Lett; 2023 Nov; 579():216462. PubMed ID: 37924937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
    Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review.
    Van Audenaerde JRM; Roeyen G; Darcy PK; Kershaw MH; Peeters M; Smits ELJ
    Pharmacol Ther; 2018 Sep; 189():31-44. PubMed ID: 29660367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-associated macrophages as a potential target to improve natural killer cell-based immunotherapies.
    Kitamura T
    Essays Biochem; 2023 Sep; 67(6):1003-1014. PubMed ID: 37313600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cells in pancreatic cancer stroma.
    Goulart MR; Stasinos K; Fincham REA; Delvecchio FR; Kocher HM
    World J Gastroenterol; 2021 Dec; 27(46):7956-7968. PubMed ID: 35046623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.
    Beelen NA; Aberle MR; Bruno V; Olde Damink SWM; Bos GMJ; Rensen SS; Wieten L
    Front Immunol; 2023; 14():1133796. PubMed ID: 37520563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy.
    Torphy RJ; Schulick RD; Zhu Y
    Mol Carcinog; 2020 Jul; 59(7):775-782. PubMed ID: 32166821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.
    Arellano-Ballestero H; Sabry M; Lowdell MW
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of pancreatic cancer.
    Sunami Y; Kleeff J
    Prog Mol Biol Transl Sci; 2019; 164():189-216. PubMed ID: 31383405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis.
    Jewett A; Kos J; Fong Y; Ko MW; Safaei T; Perišić Nanut M; Kaur K
    Semin Cancer Biol; 2018 Dec; 53():178-188. PubMed ID: 30081230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review).
    Zeng Y; Lv X; Du J
    Oncol Rep; 2021 Nov; 46(5):. PubMed ID: 34498710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
    Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive Impairment of NK Cell Cytotoxic Degranulation Is Associated With TGF-β1 Deregulation and Disease Progression in Pancreatic Cancer.
    Jun E; Song AY; Choi JW; Lee HH; Kim MY; Ko DH; Kang HJ; Kim SW; Bryceson Y; Kim SC; Kim HS
    Front Immunol; 2019; 10():1354. PubMed ID: 31281312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model.
    Lee J; Kang TH; Yoo W; Choi H; Jo S; Kong K; Lee SR; Kim SU; Kim JS; Cho D; Kim J; Kim JY; Kwon ES; Kim S
    Cancer Immunol Res; 2019 Feb; 7(2):219-229. PubMed ID: 30514792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
    Bozward AG; Warricker F; Oo YH; Khakoo SI
    Front Immunol; 2021; 12():643310. PubMed ID: 33995362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cell-mediated immunosurveillance of human cancer.
    Malmberg KJ; Carlsten M; Björklund A; Sohlberg E; Bryceson YT; Ljunggren HG
    Semin Immunol; 2017 Jun; 31():20-29. PubMed ID: 28888619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer.
    Lin M; Alnaggar M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
    Oncotarget; 2017 Nov; 8(60):101795-101807. PubMed ID: 29254205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cell-based strategies for immunotherapy of cancer.
    Vaněk O; Kalousková B; Abreu C; Nejadebrahim S; Skořepa O
    Adv Protein Chem Struct Biol; 2022; 129():91-133. PubMed ID: 35305726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.